The purpose of this study is to assess the effectiveness of oral midazolam on the delivery of care in elderly patients with moderat to severe neurocognitive disorders and opposing care.

Neurodegenerative disorders may lead to behavioral disturbances that can result in oppositional reactions, making the performance of certain medical treatments complex.

Midazolam is used to reduce anxiety and agitation in elderly patients with moderate to severe neurocognitive disorders. It has the advantages of rapid action, short half-life, and good tolerability. A recent study shows that its use by subcutaneous (SC) injection 'as needed,' off-label, is becoming increasingly common in elderly patients, particularly to facilitate care. However, SC injection may be poorly tolerated by patients, difficult to administer, and may cause a feeling of mistreatment.

The aim of this clinical trial is to evaluate the efficacy and safety of an oral form of midazolam adapted for the elderly on the performance of care.

Inclusion Criteria:

• Patient hospitalized (for a minimum estimated duration of 21 days) in a geriatric department in Medical Care and Rehabilitation, Cognitive-Behavioral Unit, or housed in a Reinforced Housing Unit, in a Long-Term Care Unit, or in a Psycho-Geriatric Unit.
• Moderate to severe cognitive impairment, defined by a MMSE (Mini Mental State Examination) score <15. If not feasible at inclusion, MMSE score <15 less than 1 year old.
• Patient opposed to care, presenting at least two episodes of opposition to care (meals excluded) for which other non-medication alternatives have failed. These refusals of care are defined by a "resistance to care" score ≥3 on the Pittsburgh scale, over the last week. In practice, the resistance to care of patients is noted in the medical record following a weekly multidisciplinary decision.

The targeted cares:

Essential nursing care (indispensable, mandatory, and prescribed) Bathing and changing made essential by obvious lack of hygiene after evaluation Bedtime installation (e.g., with the SECURIDRAP® device) technical care: blood tests, wound care, dressing changes, insertion of urinary or nasogastric tubes; administration of medication by parenteral route

• Person affiliated with social security or beneficiary of such a scheme
• Informed, written, and signed consent by the patient or their legal representative (for adults under legal protection and unable to express their consent)

Exclusion Criteria:

• Patient who has received midazolam treatment in the week before inclusion
• Patient with contraindications to midazolam:

severe Myasthenia Severe respiratory failure requiring continuous oxygen therapy Severe liver failure: PT <50% Severe sleep apnea syndrome not treated with a device Severe renal failure: Cockcroft <20mL/min Severe heart failure in a state of decompensation History of alcoholism or drug addiction

• Known hypersensitivity to the active substance, benzodiazepines, or any of the excipients
• Patient being treated concurrently with:

CYP3A4 enzyme inhibitors CYP3A4 enzyme inducers

• Weight <50 kg and >100 kg
• Gastrointestinal pathology that may limit or prevent the absorption of midazolam
• Identification of anxiety, defined by item E of the NPI (neuropsychiatric inventory) by an evaluation >2 in frequency and severity according to HAS recommendations.
• Identification of pain, defined by the Algoplus scale by an evaluation ≥2
• Identification of ideational disorders, defined by item E of the Cornell scale: E>0
• Subject in the exclusion period of another clinical trial
• Subject deprived of liberty by an administrative or judicial decision.

Blinding will be carried out upstream by the pharmacy that will prepare the treatment kits.

For each nursing treatment, the syringe will contain either midazolam or placebo according to randomization.